Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MagGenome On Path To Nanoparticle Adjuvant, Founder Seeks Investment Opportunities

Executive Summary

MagGenome, an Indian biotech which develops nanoparticle-based products, is in the early stage of research for a vaccine adjuvant. Scrip spoke to founder Sam Santhosh and CEO and chief scientific officer C N Ramchand to gauge the promise of nanotechnology and the environment in India for cell and gene therapies, among other topics, in this wide-ranging audio interview. 

MagGenome Pvt. Ltd., an Indian biotech which primarily develops magnetic nanoparticle-based products for therapeutics and molecular diagnostics, is in the early stages of research for a nanoparticle-based adjuvant for vaccines. 

MagGenome CEO C N Ramchand Company

In a podcast interview with Scrip, CEO and chief scientific officer C N Ramchand said the adjuvant offers potential to partner with vaccine companies on account of its ability to make vaccines more stable, eliminating the need for a cold chain.

In recent times, the most talked about use of the nanoparticle technology has been in Novavax, Inc.’s recombinant COVID-19 vaccine Nuvaxovid, a licensed version of which is sold in India under the Covovax brand by Serum Institute of India Pvt. Ltd.

Novavax has also developed a proprietary adjuvant Matrix-M that is used in its own products like the flu vaccine NanoFlu (currently in Phase III) and those of others - like University of Oxford’s malaria vaccine.

Along with Ramchand, founder Sam Santhosh, who has also set up other companies (MedGenome, AgriGenome and Sasken Lifesciences) via incubation vehicle SciGenom Labs Pvt Ltd, spoke to Scrip about the enabling environment being built in India for cell and gene therapy companies, the increasing linkages between novel drug discovery and diagnostics and the promise of nanotechnology.

Sam Santhosh - Founder, SciGenom Company

SciGenom also offers genetic sequencing and bioinformatics analysis to R&D institutions in India and the US. Santhosh intends to further develop an integrated incubation center by leveraging SciGenom’s data centers and R&D labs.

SciGenom Research Foundation (SGRF), set up to promote science education and research in India, has entered a tie-up with the Charotar University of Science and Technology (CHARUSAT) with an aim to jointly offer knowledge sharing opportunities, grants and PhD programs to bridge the industry-academia gap.

Despite start-ups receiving $42bn in funding in 2021, less than 15% of the unicorns were from healthcare, Santhosh points out, indicating enough headroom for healthcare start-ups to grow.

Time Stamps

00:08 Introduction

02:13 Setting Up A Genomics Incubator

03:07 Plans To Fund, Nurture Start-Ups

04:11 Challenges faced by cell and gene therapy companies in India

05:22 The promise of India 

07:00 CHARUSAT's proposition

08:46 Handholding scientists to commercial success

10:36 Where does the IP rest?

11:27 Changes in investment climate, enabling factors

13:50 Ease of exit in India

15:00 Why Are Drug Companies Investing In Diagnostics?

17:02 The Connect Between Diagnostics And Therapeutics

19:35 Genomics As Building Blocks For Better Drugs

23:30 Post COVID-19 Opportunities, Competition For MagGenome

27: 19 Investor/Venture Capital Interest?

28: 57 Nanotechnology in precision medicine

30:33 Nanoparticle adjuvant in development for vaccines



Related Stories



Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts